NHS Greenlights Free Wegovy Jabs for 1.2 Million Overweight Patients with Heart Conditions
In a significant policy shift, the NHS has approved free Wegovy injections for approximately 1.2 million people across the UK who are classified as overweight and have specific cardiovascular risks. This expansion, based on new guidelines from the National Institute for Health and Care Excellence (NICE), aims to prevent heart attacks and strokes by offering the appetite-suppressing drug to a broader population.
Expanded Eligibility Criteria for Wegovy Prescriptions
Previously, Wegovy was only available on the NHS for individuals with a Body Mass Index (BMI) of 35 or above, categorising them as obese. Under the updated NICE guidelines, the threshold has been lowered to a BMI of 27 or above, which includes those classified as overweight. However, eligibility is contingent on patients having a history of cardiovascular issues, such as a prior heart attack, stroke, or circulation problems in the legs.
This change represents a major turning point in obesity treatment, as it recognises the link between excess weight and cardiovascular health. The rollout is scheduled to begin this summer, with Wegovy being offered as a weekly injection alongside existing medications like statins.
How Wegovy Works and Its Health Benefits
Wegovy is a GLP-1 medication containing semaglutide, which functions by increasing feelings of fullness and reducing appetite to aid weight loss. Clinical trials have shown that, on average, patients lose about 21 percent of their body weight after 72 weeks of use. Beyond weight management, the drug promotes insulin release and lowers blood sugar, providing additional cardiovascular protection.
Helen Knight from NICE emphasised the importance of this decision, stating, "The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke." This extra layer of protection is expected to alleviate fears among those who have previously experienced cardiovascular events.
Expert Insights and Broader Implications
Professor Naveed Sattar, a cardiometabolic medicine expert at the University of Glasgow, welcomed the move, highlighting that it stems from high-quality trial evidence. He noted, "We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss – which in turn lowers the risk of many weight‑related conditions." This dual benefit improves patients' quality of life and addresses weight directly, beyond traditional focuses on lipids and blood pressure.
Research from The Lancet suggests that semaglutide injections may reduce cardiovascular risks regardless of weight loss, though experts advise combining the treatment with an effective exercise regime to prevent excessive muscle loss. Common side effects of Wegovy include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain
- Headache
- Tiredness
- Upset stomach
- Dizziness
- Feeling bloated
- Belching
- Low blood sugar in people with type 2 diabetes
- Gas
- Stomach flu
- Heartburn
- Runny nose or sore throat
Despite these side effects, the NHS estimates that the expanded access could significantly impact public health by reducing the burden of cardiovascular diseases. Over time, it is hoped that more medicines will be licensed for similar benefits, with costs decreasing to allow even greater societal impact.
